LEADER 00000cam a2200721 i 4500
001 on1148889539
003 OCoLC
005 20210702123040.7
006 m o d
007 cr un|||||||||
008 200602s2020 dcua obt 000 0 eng
016 7 101768402|2DNLM
019 1147904209|a1156664582
020 9780309672115
020 0309672112
020 9780309672139|q(electronic book)
020 0309672139|q(electronic book)
020 |z9780309672108|q(paperback)
020 |z0309672104|q(paperback)
035 (OCoLC)1148889539|z(OCoLC)1147904209|z(OCoLC)1156664582
040 NLM|beng|erda|epn|cNLM|dEBLCP|dYDX|dN$T|dUKAHL|dOCLCF
|dOCLCO|dNLM|dOCLCO|dOCLCQ|dOCLCO|dOCLCA
042 pcc
043 n-us---
049 RIDW
050 4 RC158
082 04 166.9/362|223
090 RC158
245 00 Assessment of long-term health effects of antimalarial
drugs when used for prophylaxis /|cDavid A. Savitz and
Anne N. Styka, editors ; Committee to Review Long-Term
Health Effects of Antimalarial Drugs, Board on Population
Health and Public Health Practice, Health and Medicine
Division.
264 1 Washington, DC :|bThe National Academies Press,|c[2020]
300 1 online resource (1 PDF file (xvii, 407 pages)) :
|billustrations.
336 text|btxt|2rdacontent
337 computer|bc|2rdamedia
338 online resource|bcr|2rdacarrier
347 text file|2rdaft
490 1 A consensus study report of the National Academies of
Sciences, Engineering, Medicine
504 Includes bibliographical references.
505 0 Intro -- FrontMatter -- Reviewers -- Preface -- Contents -
- Acronyms and Abbreviations -- Summary -- 1 Introduction
-- 2 Background -- 3 Identification and Evaluation of the
Evidence Base -- 4 Mefloquine -- 5 Tafenoquine -- 6
Atovaquone/Proguanil -- 7 Doxycycline -- 8 Primaquine -- 9
Chloroquine -- 10 Improving the Quality of Research on the
Long-Term Health Effects of Antimalarial Drugs -- Appendix
A: Public Meeting Agendas -- Appendix B: Invited
Presentations -- Appendix C: Epidemiologic Studies That
Met the Committee's Inclusion Criteria
520 3 Among the many who serve in the United States Armed Forces
and who are deployed to distant locations around the world,
myriad health threats are encountered. In addition to
those associated with the disruption of their home life
and potential for combat, they may face distinctive
disease threats that are specific to the locations to
which they are deployed. U.S. forces have been deployed
many times over the years to areas in which malaria is
endemic, including in parts of Afghanistan and Iraq.
Department of Defense (DoD) policy requires that
antimalarial drugs be issued and regimens adhered to for
deployments to malaria-endemic areas. Policies directing
which should be used as first and as second-line agents
have evolved over time based on new data regarding adverse
events or precautions for specific underlying health
conditions, areas of deployment, and other operational
factors At the request of the Veterans Administration,
Assessment of Long-Term Health Effects of Antimalarial
Drugs When Used for Prophylaxis assesses the scientific
evidence regarding the potential for long-term health
effects resulting from the use of antimalarial drugs that
were approved by FDA or used by U.S. service members for
malaria prophylaxis, with a focus on mefloquine,
tafenoquine, and other antimalarial drugs that have been
used by DoD in the past 25 years. This report offers
conclusions based on available evidence regarding
associations of persistent or latent adverse events.
536 This activity was supported by Contract Order No. VA
36C24E18C0067 between the National Academy of Sciences and
the Department of Veterans Affairs. Any opinions, findings,
conclusions, or recommendations expressed in this
publication do not necessarily reflect the views of any
organization or agency that provided support for the
project.
588 0 Online resource; title from PDF title page (viewed July 8,
2020).
590 eBooks on EBSCOhost|bEBSCO eBook Subscription Academic
Collection - North America
650 0 Malaria|0https://id.loc.gov/authorities/subjects/
sh85080038|xEvaluation.|0https://id.loc.gov/authorities/
subjects/sh00005674
650 0 Malaria|0https://id.loc.gov/authorities/subjects/
sh85080038|xDiagnosis.|0https://id.loc.gov/authorities/
subjects/sh99005546
650 7 Malaria.|2fast|0https://id.worldcat.org/fast/1006343
650 7 Evaluation.|2fast|0https://id.worldcat.org/fast/916975
650 7 Malaria|xDiagnosis.|2fast|0https://id.worldcat.org/fast/
1006347
651 2 United States.|0https://id.nlm.nih.gov/mesh/D014481
655 2 Systematic Review.|0https://id.nlm.nih.gov/mesh/D000078182
655 4 Electronic books.
655 7 Technical reports.|2lcgft|0https://id.loc.gov/authorities/
genreForms/gf2015026093
655 7 Technical reports.|2fast|0https://id.worldcat.org/fast/
1941336
700 1 Savitz, David A.,|0https://id.loc.gov/authorities/names/
n86076608|eeditor.
700 1 Styka, Anne N.,|0https://id.loc.gov/authorities/names/
no2017048150|eeditor.
710 2 National Academies of Sciences, Engineering, and Medicine
(U.S.).|bCommittee to Review Long-Term Health Effects of
Antimalarial Drugs,|0https://id.loc.gov/authorities/names/
n2020184350|eissuing body.
776 08 |iPrint version:|aNational Academies of Sciences,
Engineering, and Medicine.|tAssessment of Long-Term Health
Effects of Antimalarial Drugs When Used for Prophylaxis.
|dWashington, D.C. : National Academies Press, ©2020
830 0 Consensus study report.|0https://id.loc.gov/authorities/
names/n2017188206
856 40 |uhttps://rider.idm.oclc.org/login?url=https://
search.ebscohost.com/login.aspx?direct=true&scope=site&
db=nlebk&AN=2490668|zOnline ebook via EBSCO. Access
restricted to current Rider University students, faculty,
and staff.
856 42 |3Instructions for reading/downloading the EBSCO version
of this ebook|uhttp://guides.rider.edu/ebooks/ebsco
901 MARCIVE 20231220
948 |d20210708|cEBSCO|tEBSCOebooksacademic NEW 5016 |lridw
994 92|bRID
